Contract analysis

I. EXECUTIVE SUMMARY This memorandum summarizes the key documents identified during my review of the document production served by Apex Surgical Innovations, Inc. ("Apex") on October 7, 2024. The production comprises 31,450 documents bearing Bates numbers APEX-000001 through APEX-031450, produced in response to Solstice Biomedical Devices Ltd.'s ("Solstice") First Set of Requests for Production of Documents (38 reque

1. Prosecution Correspondence and PTO File Histories — Documents revealing the prosecution history of the three asserted patents, including narrowing amendments, examiner interview summaries, and internal strategy discussions that bear directly on claim construction and prosecution history estoppel.

2. Inventor Notebooks and Development Records of Dr. Raymond Szabo — Scanned laboratory notebooks and technical records documenting the conception, development, and reduction to practice of the claimed inventions, including references to prior art and competitor products that may not have been disclosed to the United States Patent and Trademark Office ("USPTO").

3. Prior Art References Known to Apex — Internal prior art search reports, duty-of-candor discussions, freedom-to-operate analyses, and post-issuance validity assessments that identify prior art references directly relevant to Solstice's invalidity defenses and inequitable conduct counterclaim.

4. Prior Licensing Agreements and Negotiations — Executed license agreements, term sheets, and negotiation correspondence involving the asserted patents, which provide comparable-license benchmarks critical to the damages analysis under the Georgia-Pacific reasonable royalty framework.

5. Commercial Documents Relevant to Damages — Internal sales reports, financial projections, marketing analyses, and corporate communications that bear on the reasonable royalty base, Apex's competitive motivations for filing this action, and the methodological soundness of Apex's claimed damages. These findings have significant implications for Solstice's defenses of non-infringement, invalidity under 35 U.S.C. §§ 1

II. SCOPE AND METHODOLOGY OF REVIEW A. Production Overview Apex served its document production on October 7, 2024, via secure FTP transfer to DataVault Litigation Solutions, LLC. The production was made in response to Solstice's First Set of Requests for Production of Documents, comprising 38 individual requests served on August 19, 2024. The production contains a total of 31,450 documents, with Bates numbers running

III. CATEGORY 1: PROSECUTION CORRESPONDENCE AND PTO FILE HISTORIES A. Overview. The Apex production includes a substantial volume of internal and external correspondence relating to the prosecution of the three asserted patents — the '237 Patent, the '884 Patent, and the '105 Patent — before the USPTO. These documents encompass communications between Apex's in-house intellectual property team, led by Dr. Priya Chandr

1. Cross-reference with prior art analysis. The prosecution documents should be cross-referenced with the prior art analysis being conducted by Dr. Jonathan Kendrick of Kendrick & Lau LLP. In particular, the prior art references discussed in APEX-004520 (the Chandrasekaran-to-Hale memorandum regarding the '237 Patent) should be compared against the references already identified in our Preliminary Invalidity Contentio

2. Prioritize for claim construction briefing. The following documents should be flagged as priority exhibits for claim construction briefing in advance of the Markman hearing scheduled for November 18, 2024: • APEX-004401 through APEX-004415 (draft claim amendments for the '237 Patent, relevant to "resilient sealing member" and "locking seal assembly" construction); • APEX-007891 through APEX-007934 (prosecution cor

3. Coordinate with invalidity expert. The prior art references identified in the prosecution correspondence — particularly those discussed in APEX-004520 and in the '884 Patent prosecution file — should be provided to Dr. Miriam Ostrowski (Halford University), our retained invalidity expert, for incorporation into her expert report. Dr. Ostrowski should assess whether Apex's characterizations of the prior art during

IV. CATEGORY 2: INVENTOR NOTEBOOKS AND DEVELOPMENT RECORDS OF DR. RAYMOND SZABO A. Overview. The Apex production includes scanned copies of laboratory notebooks and technical development records authored by Dr. Raymond Szabo, the named inventor on all three asserted patents. Dr. Szabo has served as Apex's Vice President of Engineering since approximately 2011 and led the team responsible for developing the locking se

1. Expert analysis. The complete notebook series (APEX-014001 through APEX-014287) should be provided to Dr. Miriam Ostrowski for detailed technical analysis. Dr. Ostrowski should be instructed to focus on (a) the design concepts at APEX-014045 through APEX-014062 and their relationship to known prior art, (b) the journal article referenced at APEX-014123 and its potential as an anticipatory reference, and (c) the de

2. Prior art investigation. The journal article referenced at APEX-014123 must be identified, located, and reviewed in full. Efforts should be made to obtain a complete copy of the article and to confirm its publication date. If the publication date is prior to the earliest effective filing date of the '105 Patent, the article should be analyzed for its disclosure of claimed elements and incorporated into the invalid

3. Inequitable conduct assessment. The email at APEX-014255 should be assessed for its implications for Solstice's inequitable conduct counterclaim. This assessment should include (a) determining whether the referenced competitor product or any associated publications or patents were disclosed in any Information Disclosure Statement during prosecution of the '237, '884, or '105 Patents; (b) identifying the specific c

V. CATEGORY 3: PRIOR ART REFERENCES KNOWN TO APEX A. Overview. The Apex production includes a category of documents relating to prior art references that were known to Apex during the prosecution of the asserted patents and in the post-issuance period. These documents include internal prior art search reports commissioned by Apex, communications within Apex's IP department discussing the relevance of identified prior

1. Cross-reference with Kendrick & Lau LLP. The prior art references in APEX-016500 through APEX-016578 should be cross-referenced against the prior art references already identified by Kendrick & Lau LLP and incorporated into the invalidity contentions. Any new references identified in the Apex search report that were not previously known to us should be analyzed for their relevance and added to the invalidity conte

2. Inequitable conduct analysis. APEX-016612 should be flagged as a critical document for the inequitable conduct counterclaim. A detailed analysis should be prepared comparing the prior art references discussed in the email chain against the Information Disclosure Statements filed during prosecution of each asserted patent, to determine which references were and were not ultimately disclosed.

3. Coordination with invalidity contentions. These materials should be incorporated into the Invalidity Contentions, supplementing the Prior Art Analysis Memorandum dated September 18, 2024. Christy Bauer should coordinate with Kendrick & Lau LLP and Dr. Ostrowski on updating the invalidity charts to reflect the newly identified references.

4. Veridian subpoena. The Subpoena Duces Tecum issued to Veridian Medical Technologies, Inc. on September 12, 2024, may yield additional documents that corroborate the prior art references identified in Apex's FTO analysis. The return date for that subpoena is approaching, and we should follow up to confirm compliance.

VI. CATEGORY 4: PRIOR LICENSING AGREEMENTS AND NEGOTIATIONS A. Overview. The Apex production includes license agreements and related negotiation correspondence involving the asserted patents and the broader Apex Trocar Patent Family, which encompasses 14 issued patents and 6 pending patent applications. These documents were produced in response to Solstice's requests for production of all licensing agreements, term s

1. The 4.5% rate in the 2020 license and the 2.8% rate in the 2022 license provide concrete benchmarks for rebutting Apex's damages expert Hugh Danaher's claimed $31,800,000 in reasonable royalty damages. Danaher's figure implies an effective royalty rate of approximately 8.2%, which is nearly double the highest rate Apex has actually accepted in a comparable transaction and nearly triple the rate for the '105 Patent

2. The failed 2023 negotiation demonstrates that the market does not support Apex's high royalty demands. The counterparty's decision to design around the patents rather than accept a 6% royalty rate and $5,000,000 lump sum underscores that Apex's initial demands are not reflective of the true market value of the technology.

3. The negotiation history from the 2020 license (initial demand of 7%, ultimate agreement at 4.5%) reveals Apex's pattern of demanding significantly higher rates than it is ultimately willing to accept, which should inform both the damages analysis and the settlement negotiations. These documents should be provided to Dr. Elena Marchetti at Pinnacle Economics Group LLC, Solstice's retained damages expert, for integr